Trial Profile

A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK-6598 (Primary) ; Pembrolizumab (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

19 Jun 2025 Status changed from active, no longer recruiting to completed.
30 Apr 2025 Results assessing the safety, tolerability, PK, and antitumor activity of MK-6598,presented at the 116th Annual Meeting of the American Association for Cancer Research
16 Apr 2025 Planned End Date changed from 13 Dec 2027 to 27 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com